Md Rafiqul Islam1, John Attia2, Liaquat Ali3, Mark McEvoy2, Shahjada Selim4, David Sibbritt5, Ayesha Akhter6, Shahnaz Akter7, Roseanne Peel2, Omar Faruque3, Tazreen Mona8, Hafiza Lona9, Abul Hasnat Milton10. 1. CCEB, School of Medicine and Public Health, The University of Newcastle and Hunter Medical Research Institute, Kookaburra Close, New Lambton Heights, Newcastle, NSW, Australia; Goulburn Valley Health, Shepparton, VIC, Australia; RHAC, the University of Melbourne, Shepparton, VIC 3630, Australia. 2. CCEB, School of Medicine and Public Health, The University of Newcastle and Hunter Medical Research Institute, Kookaburra Close, New Lambton Heights, Newcastle, NSW, Australia. 3. Bangladesh University of Health Sciences, Mirpur, Dhaka, Bangladesh. 4. Bangabandhu Sheikh Mujib Medical University, Shahbag, Dhaka, Bangladesh. 5. University Technology Sydney, Sydney, NSW, Australia. 6. Goulburn Valley Health, Shepparton, VIC, Australia. 7. Institute of Child and Mother Health (ICMH), Demra, Matuail, Dhaka, Bangladesh. 8. Centre for Health and Development (CHAD), West Rampura, Dhaka, Bangladesh. 9. Medical College for Women, Uttara, Dhaka, Bangladesh. 10. CCEB, School of Medicine and Public Health, The University of Newcastle and Hunter Medical Research Institute, Kookaburra Close, New Lambton Heights, Newcastle, NSW, Australia. Electronic address: Milton.Hasnat@newcastle.edu.au.
Abstract
AIMS: There are a number of studies showing that zinc supplementation may improve glucose handling in people with established diabetes. We sought to investigate whether this zinc-dependent improvement in glucose handling could potentially be harnessed to prevent the progression of pre-diabetes to diabetes. In this double-blind randomized placebo-controlled trial, we determined participants' fasting blood glucose levels, (FBG) and Homeostasis Model Assessment (HOMA) parameters (beta cell function, insulin sensitivity and insulin resistance) at baseline and after 6 months of zinc supplementation. METHODS:The Bangladesh Institute of Health Sciences Hospital (BIHS) (Mirpur, Dhaka, Bangladesh) database was used to identify 224 patients with prediabetes, of whom 55 met the inclusion criteria and agreed to participate. The participants were randomized either to the intervention or control group using block randomization. The groups received either 30mg zinc sulphate dispersible tablet or placebo, once daily for six months. RESULTS: After six months, the intervention group significantly improved their FBG concentration compared to the placebo group (5.37±0.20mmol/L vs 5.69±0.26, p<0.001) as well as compared to their own baseline (5.37±0.20mmol/L vs 5.8±0.09, p<0.001). Beta cell function, insulin sensitivity and insulin resistance all showed a statistically significant improvement as well. CONCLUSION: To our knowledge this is the first trial to show an improvement in glucose handling using HOMA parameters in participants with prediabetes. Larger randomized controlled trials are warranted to confirm these findings and to explore clinical endpoints.
RCT Entities:
AIMS: There are a number of studies showing that zinc supplementation may improve glucose handling in people with established diabetes. We sought to investigate whether this zinc-dependent improvement in glucose handling could potentially be harnessed to prevent the progression of pre-diabetes to diabetes. In this double-blind randomized placebo-controlled trial, we determined participants' fasting blood glucose levels, (FBG) and Homeostasis Model Assessment (HOMA) parameters (beta cell function, insulin sensitivity and insulin resistance) at baseline and after 6 months of zinc supplementation. METHODS: The Bangladesh Institute of Health Sciences Hospital (BIHS) (Mirpur, Dhaka, Bangladesh) database was used to identify 224 patients with prediabetes, of whom 55 met the inclusion criteria and agreed to participate. The participants were randomized either to the intervention or control group using block randomization. The groups received either 30mg zinc sulphate dispersible tablet or placebo, once daily for six months. RESULTS: After six months, the intervention group significantly improved their FBG concentration compared to the placebo group (5.37±0.20mmol/L vs 5.69±0.26, p<0.001) as well as compared to their own baseline (5.37±0.20mmol/L vs 5.8±0.09, p<0.001). Beta cell function, insulin sensitivity and insulin resistance all showed a statistically significant improvement as well. CONCLUSION: To our knowledge this is the first trial to show an improvement in glucose handling using HOMA parameters in participants with prediabetes. Larger randomized controlled trials are warranted to confirm these findings and to explore clinical endpoints.
Authors: Andrea J Lobene; Joseph M Kindler; Nathan T Jenkins; Norman K Pollock; Emma M Laing; Arthur Grider; Richard D Lewis Journal: J Nutr Date: 2017-06-07 Impact factor: 4.798
Authors: Mirthe Muilwijk; Mary Nicolaou; Samera A Qureshi; Carlos Celis-Morales; Jason M R Gill; Aziz Sheikh; Naveed Sattar; Erik Beune; Anne Karen Jenum; Karien Stronks; Irene G M van Valkengoed Journal: PLoS One Date: 2018-07-16 Impact factor: 3.240